Search results for "Rash"

showing 10 items of 377 documents

FRI0504 Prognostic Factors of Adult Onset Still's Disease: Analysis of 100 Cases in 3 Tertiary Referral Centers

2016

Background Adult onset Still9s disease (AOSD) is rare inflammatory disease [1]. Three different patterns of AOSD have been identified: i. monocyclic pattern, characterized by a systemic single episode; ii. polycyclic pattern, associated with multiple flares, separated by remissions; iii. chronic pattern, related to a persistently active disease with associated polyarthritis [2]. Until now, the treatment of AOSD remains largely empirical, lacking controlled clinical trials [1]. Objectives We aimed to investigate clinical data of AOSD patients and any possible correlation among these features and the outcome of patients. Methods Clinical data of 100 AOSD patients were recorded. All patients f…

medicine.medical_specialtyImmunologyArthritisGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTocilizumabRheumatologyInternal medicinemedicineImmunology and Allergy030212 general & internal medicine030203 arthritis & rheumatologyAnakinramedicine.diagnostic_testbusiness.industrymedicine.diseaseRashSurgerychemistryErythrocyte sedimentation rateMacrophage activation syndromePolyarthritismedicine.symptombusinessComplicationmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Significance of I313V mutation of NLPR3 gene in two pediatric patients

2011

Results Both case #1 (M.T) and #2 (V.C) displayed a mild clinical phenotype (episodes of urticarial rash and arthralgia associated with elevation of acute phase reactants), compatible with FCAS and Muckle-Wells syndrome, respectively. Both patients displayed good response to NSAID and/or steroid on demand. Compared to HD controls, patients displayed enhanced and delayed IL1b secretion. This was accompanied by higher levels of lL1Ra and IL-6 without any significant differences in IL-8. Interestingly, parents carrying the mutation also displayed higher levels of secreted IL-1b compared to HD control group. Conclusion The I313V mutation is associated with a mild CAPS phenotype and with an incr…

medicine.medical_specialtyMutationlcsh:Diseases of the musculoskeletal systembusiness.industryAcute-phase proteinlcsh:RJ1-570lcsh:Pediatricsmedicine.disease_causePhenotypeRheumatologyEndocrinologyRheumatologyUrticarial rashInternal medicineOn demandPoster PresentationPediatrics Perinatology and Child HealthmedicineImmunology and AllergySecretionPediatrics Perinatology and Child Healthlcsh:RC925-935businessGenePediatric Rheumatology
researchProduct

Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: A case report.

2021

RATIONALE: Pityriasis rosea Gibert is an erythematous-papulosquamous dermatosis that frequently occurs in young adults. The etiopathogenesis of PR is still unknown, but is frequently associated with episodes of upper respiratory tract infections. It is likely that a new viral trigger of pityriasis rosea is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PATIENT CONCERNS: We present the case of a female patient in whom the diagnosis of pityriasis rosea led to the investigation and diagnosis of the SARS-CoV-2 infection. The patient presented to the Department of Dermatology for a 3 week duration of an extremely pruritic erythematous-squamous lesion, initially on the trunk …

medicine.medical_specialtyPityriasis RoseaContext (language use)Lesion03 medical and health sciencescoronavirus disease 20190302 clinical medicineAdrenal Cortex HormonesmedicineHumans030212 general & internal medicineClinical Case ReportRespiratory tract infectionsbusiness.industrySARS-CoV-24900COVID-19pityriasis rosea GibertGeneral MedicineMiddle Agedmedicine.diseaseDermatologyRashTopical medicationmedicine.anatomical_structure030220 oncology & carcinogenesisPityriasis roseaEtiologyFemalemedicine.symptombusinessRespiratory tractResearch Articlesevere acute respiratory syndrome coronavirus 2Medicine
researchProduct

Explaining self-reported traffic crashes of cyclists: An empirical study based on age and road risky behaviors

2019

Abstract The growing rates of traffic crashes involving cyclists are currently recognized as a major public health and road safety concern. Furthermore, risky behaviors on the road and their precedent factors have been conceptualized as potential determinants for explaining, intervening and preventing traffic injuries of cyclists. Objectives This study aimed at examining whether individual factors and self-reported risky behaviors could explain the crash rates of cyclists in a period of 5 years. Methods A sample of 1064 cyclists was used, with a mean age of 32.83 years. Participants answered a survey assessing demographic data and information on risky behaviors, risk perception, knowledge o…

medicine.medical_specialtyPublic health05 social sciencesApplied psychology0211 other engineering and technologiesPublic Health Environmental and Occupational HealthCrashSample (statistics)Mean age02 engineering and technologyStructural equation modelingRisk perceptionEmpirical research021105 building & constructionmedicine0501 psychology and cognitive sciencesSafety Risk Reliability and QualityPsychologyhuman activitiesSafety Research050107 human factorsDifferential impactSafety Science
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct

Refractory Perianal Ulcers in a Neonate. Beyond the Diaper Rash

2016

medicine.medical_specialtyRefractorybusiness.industryDiaper rashMedicinebusinessmedicine.diseaseDermatologyJournal of Dermatology Research and Therapy
researchProduct

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

2018

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July …

medicine.medical_specialtySocio-culturaleHormone-receptor positiveExemestane03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerElderlyExemestaneWeight lossInternal medicineAdvanced breast cancer; Elderly; Everolimus; Exemestane; Hormone-receptor positive; OncologymedicineEverolimus030212 general & internal medicineStomatitisPneumonitisAdvanced breast cancer; Elderly; Everolimus; Exemestane; Hormone-receptor positiveEverolimusbusiness.industryCancermedicine.diseaseRashEverolimuchemistryOncology030220 oncology & carcinogenesisMED/06 - ONCOLOGIA MEDICAAdvanced breast cancermedicine.symptombusinessResearch Papermedicine.drug
researchProduct

AB0427 Clinical and laboratory findings in patients with late-onset sle and correlations with il6 concentrations

2013

Background Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease that usually develops in women aged 18-50 years. It is known that age at onset modifies the clinical manifestations of SLE, and so the elderly may form a specific patient subgroup. It is now well established that the serum levels of the cytokines interleukin (IL) 6 and IL10 are increased in patients with SLE (1). Objectives The primary aim was to compare the type of clinical involvement and autoantibodies in patients with late-onset (LO) or early-onset (EO) SLE. The second aim was to compare IL6 levels in the two patient groups and their possible correlations with clinical and immunological manifestations. Meth…

medicine.medical_specialtySystemic lupus erythematosusAnti-nuclear antibodybusiness.industryImmunologyAutoantibodyArthritismedicine.diseaseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyRheumatologyRheumatologyimmune system diseasesInternal medicineImmunologymedicineImmunology and AllergyAge of onsetmedicine.symptomskin and connective tissue diseasesMalar rashbusinessSerositisAnnals of the Rheumatic Diseases
researchProduct

5PSQ-100 Comparative analysis of the safety and tolerability profile of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis

2020

Background and importance The main treatments for idiopathic pulmonary fibrosis are pirfenidone and nintedanib. Although their efficacy is known, further studies are needed to evaluate the safety and tolerability profiles (STPs) based on real world data. Aim and objectives The aim of this study was to evaluate the STP of nintedanib and pirfenidone according to our hospital data. Material and methods We analysed 148 patients treated with pirfenidone (72% men; 28% women) and 120 treated with nintedanib (77% men; 23% women) from September 2016 to September 2019. The average age of the patients treated with pirfenidone and nintedanib was 72.7 and 74.4 years, respectively. Drug tolerability was …

medicine.medical_specialtybusiness.industryNauseaPirfenidonemedicine.diseaseRashGastroenterologychemistry.chemical_compoundIdiopathic pulmonary fibrosischemistryTolerabilityWeight lossInternal medicinemedicineVomitingNintedanibmedicine.symptombusinessmedicine.drugSection 5: Patient Safety and Quality assurance
researchProduct

Synthesis of the Data on COVID-19 Skin Manifestations: Underlying Mechanisms and Potential Outcomes

2021

Abstract The incidence of coronavirus disease 2019 (COVID-19)-related skin manifestations has progressively grown, in parallel with the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreading. The available evidence indicates that cutaneous signs are heterogeneous and can be divided as follows: a) erythematous rashes, b) lesions of vascular origin, c) vesicular rashes, d) urticarial rashes, and e) acute generalized exanthematous pustulosis (AGEP), erythema multiforme (EM) and other polymorphic/atypical reactions. Most cutaneous manifestations appear simultaneously or after respiratory and/or systemic symptoms such as fever, even if rarely urticaria has been reported as…

medicine.medical_specialtycutaneous manifestationscutaneous manifestationbusiness.industrySARS-CoV-2COVID-19DermatologyDiseaseReviewmedicine.diseaseAcute generalized exanthematous pustulosisDermatologyVirusHypersensitivity reactionImmune systemmedicineskin rashesErythema multiformeRespiratory systemChilblainsbusiness
researchProduct